{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T14:21:56Z","timestamp":1771078916734,"version":"3.50.1"},"reference-count":17,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,2,8]],"date-time":"2020-02-08T00:00:00Z","timestamp":1581120000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.nrleng.2020.02.001","type":"journal-article","created":{"date-parts":[[2020,2,15]],"date-time":"2020-02-15T22:46:38Z","timestamp":1581806798000},"page":"346-352","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Progression of a series of patients with relapsing-remitting multiple sclerosis treated for 7 years with natalizumab using the \u201cno evidence of disease activity\u201d parameter"],"prefix":"10.1016","volume":"36","author":[{"given":"A.","family":"Pato Pato","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Costa Arp\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Rodr\u00edguez Regal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Rodr\u00edguez Constenla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Cimas Hernando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Mu\u00f1oz Pousa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Naya R\u00edos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.R.","family":"Lorenzo Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.C.","family":"Amigo Jorr\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.M.","family":"Prieto Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nrleng.2020.02.001_bib0005","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1007\/s11910-013-0390-z","article-title":"Monoclonal antibodies as disease modifying therapy in multiple sclerosis","volume":"13","author":"Longbrake","year":"2013","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/j.nrleng.2020.02.001_bib0010","unstructured":"Biogen Idec. TYSABRI\u00ae (natalizumab) intravenous injec-tion monoclonal antibody. 2013. Food and Drug Admi-nistration. Reference ID: 3753128. Available from: http:\/\/www.tysabri.com\/prescribingInfo."},{"key":"10.1016\/j.nrleng.2020.02.001_bib0015","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1177\/1756285615605429","article-title":"Monoclonal antibody therapies for the treatment of relapsing-remitting multiple sclerosis: differentiating mechanisms and clinical outcomes","volume":"8","author":"Lycke","year":"2015","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.nrleng.2020.02.001_bib0020","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1007\/s00415-011-6116-8","article-title":"Progressive multifocal leukoencephalopathy and natalizumab","volume":"258","author":"Hellwig","year":"2011","journal-title":"J Neurol"},{"key":"10.1016\/j.nrleng.2020.02.001_bib0025","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/ana.24286","article-title":"Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"76","author":"Plavina","year":"2014","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nrleng.2020.02.001_bib0030","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1055\/s-0036-1579695","article-title":"Parenteral treatment of multiple sclerosis: The advent of monoclonal antibodies","volume":"36","author":"Barry","year":"2016","journal-title":"Semin Neurol"},{"key":"10.1016\/j.nrleng.2020.02.001_bib0035","unstructured":"EMA\/137488\/2016. EMA confirms recommendations to minimise risk of brain infection PML with Tysabri. [accessed 2016].Available from: http:\/\/www.ema.europa.eu\/docs\/enGB\/documentlibrary\/Pressrelease\/2016\/02\/WC500202389.pdf."},{"key":"10.1016\/j.nrleng.2020.02.001_bib0040","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.nrl.2013.10.004","article-title":"Consenso espa\u00f1ol actualizado sobre el uso del natalizumab (Tysabri\u00ae)- 2013","volume":"30","author":"Fern\u00e1ndez","year":"2015","journal-title":"Neurolog\u00eda"},{"key":"10.1016\/j.nrleng.2020.02.001_bib0045","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1093\/brain\/awv105","article-title":"Defining high, medium and low impact prognostic factorsfor developing multiple sclerosis","volume":"138","author":"Tintor\u00e9","year":"2015","journal-title":"Brain"},{"key":"10.1016\/j.nrleng.2020.02.001_bib0050","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S1474-4422(09)70021-3","article-title":"Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study","volume":"8","author":"Havrdova","year":"2009","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nrleng.2020.02.001_bib0055","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nrleng.2020.02.001_bib0060","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1007\/s00415-012-6414-9","article-title":"Natalizumab treatment of multiple sclerosis in Spain: Results of an extensive observational study","volume":"259","author":"Fern\u00e1ndez","year":"2012","journal-title":"J Neurol"},{"key":"10.1016\/j.nrleng.2020.02.001_bib0065","doi-asserted-by":"crossref","first-page":"321","DOI":"10.33588\/rn.5206.2010766","article-title":"Estudio observacional sobre la efectividad y seguridad del natalizumab en el tratamiento de la esclerosis m\u00faltiple","volume":"52","author":"Horga","year":"2011","journal-title":"Rev Neurol"},{"key":"10.1016\/j.nrleng.2020.02.001_bib0070","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jns.2016.03.025","article-title":"Long-term assessment of no evidence of disease activity with natalizumab in relapsing multiple sclerosis","volume":"364","author":"Prosperini","year":"2016","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.nrleng.2020.02.001_bib0075","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1177\/1352458515624975","article-title":"Clinical 3-tesla FLAIR* MRI improves diagnostic accuracy in multiple sclerosis","volume":"22","author":"George","year":"2016","journal-title":"Mult Scler"},{"key":"10.1016\/j.nrleng.2020.02.001_bib0080","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1001\/jamaneurol.2014.3537","article-title":"Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort","volume":"72","author":"Rotstein","year":"2015","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.nrleng.2020.02.001_bib0085","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1177\/1352458515616701","article-title":"Inclusion of brain volume loss in a revised measure of \u201cno evidence of disease activity\u201d (NEDA-4) in relapsing-remitting multiple sclerosis","volume":"22","author":"Kappos","year":"2016","journal-title":"Mult Scler"}],"container-title":["Neurolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173580820300055?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173580820300055?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T03:31:36Z","timestamp":1761881496000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2173580820300055"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S2173580820300055"],"URL":"https:\/\/doi.org\/10.1016\/j.nrleng.2020.02.001","relation":{},"ISSN":["2173-5808"],"issn-type":[{"value":"2173-5808","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Progression of a series of patients with relapsing-remitting multiple sclerosis treated for 7 years with natalizumab using the \u201cno evidence of disease activity\u201d parameter","name":"articletitle","label":"Article Title"},{"value":"Neurolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nrleng.2020.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.nrl.2018.02.003","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Sociedad Espa\u00f1ola de Neurolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}